Epidemiology of Hepatitis C Virus: People Who Inject Drugs and Other Key Populations
暂无分享,去创建一个
[1] B. Hoen,et al. Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV , 2018, AIDS.
[2] S. Mauss,et al. Direct‐acting antiviral treatment of chronic HCV‐infected patients on opioid substitution therapy: Still a concern in clinical practice? , 2018, Addiction.
[3] C. Boucher,et al. Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] C. Latkin,et al. Understanding and addressing hepatitis C reinfection in the oral direct‐acting antiviral era , 2018, Journal of viral hepatitis.
[5] B. Lindenbach,et al. Recovery of Infectious Hepatitis C Virus From Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs , 2018, The Journal of infectious diseases.
[6] I. Veldhuijzen,et al. Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries , 2018, BMC Infectious Diseases.
[7] D. Holtzman,et al. Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014 , 2018, American journal of public health.
[8] N. Hill,et al. Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review , 2017, BMC Infectious Diseases.
[9] P. Krajči,et al. Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model , 2017, European journal of gastroenterology & hepatology.
[10] J. Leung,et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review , 2017, The Lancet. Global health.
[11] J. Leung,et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review , 2017, The Lancet. Global health.
[12] A. Hogewoning,et al. Men who have sex with men starting pre-exposure prophylaxis (PrEP) are at risk of HCV infection: evidence from the Amsterdam PrEP study. , 2017, AIDS.
[13] G. Dore,et al. HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs , 2017, Current HIV/AIDS Reports.
[14] D. Nelson,et al. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. , 2017, Annals of internal medicine.
[15] V. Martel-Laferrière,et al. Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] H. Stellbrink,et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. , 2017, Journal of hepatology.
[17] H. El‐Serag,et al. Global epidemiology and burden of HCV infection and HCV-related disease , 2017, Nature Reviews Gastroenterology &Hepatology.
[18] S. Little,et al. Can research at the end of life be a useful tool to advance HIV cure? , 2017, AIDS.
[19] R. Chou,et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. , 2016, The Lancet. Infectious diseases.
[20] P. Mateu-Gelabert,et al. Inactivation of HCV and HIV by microwave: a novel approach for prevention of virus transmission among people who inject drugs , 2016, Scientific Reports.
[21] A. Petruzziello,et al. Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe , 2016, Infectious Agents and Cancer.
[22] J. Macías,et al. HCV epidemiology in high-risk groups and the risk of reinfection. , 2016, Journal of hepatology.
[23] Reza Assadi,et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.
[24] J. Cairns,et al. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation , 2016, Journal of hepatology.
[25] P. Easterbrook,et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. , 2016, The Lancet. Infectious diseases.
[26] P. Vickerman,et al. Is increased hepatitis C virus case‐finding combined with current or 8‐week to 12‐week direct‐acting antiviral therapy cost‐effective in UK prisons? A prevention benefit analysis , 2016, Hepatology.
[27] D. De Angelis,et al. New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England , 2016, Journal of viral hepatitis.
[28] C. Sabin,et al. Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] H. Thiede,et al. Reduction in Needle Sharing Among Seattle-Area Injection Drug Users Across 4 Surveys, 1994-2013. , 2016, American journal of public health.
[30] R. Riley,et al. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] D. Y. Kim,et al. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm – volume 3 , 2015, Journal of viral hepatitis.
[32] Lorie A. Kloda,et al. The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis , 2015, PloS one.
[33] S. Bird,et al. Corrigendum to “National record linkage study of mortality for a large cohort of opioid users ascertained by drug treatment or criminal justice sources in England, 2005–2009” [Drug Alcohol Depend. 146 (2015) 17–23] , 2015, Drug and alcohol dependence.
[34] Todd M. Allen,et al. Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study. , 2015, The Journal of infectious diseases.
[35] A. Mocroft,et al. Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[36] H. Hagan,et al. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men , 2015, AIDS.
[37] H. Hagan,et al. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. , 2015, The International journal on drug policy.
[38] G. Dore,et al. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention , 2015, Current opinion in HIV and AIDS.
[39] G. Dore,et al. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States , 2015, Annals of Internal Medicine.
[40] C. Katlama,et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. , 2015, The lancet. HIV.
[41] Q. Gong,et al. Prediction of virological response by pretreatment hepatitis B virus reverse transcriptase quasispecies heterogeneity: the advantage of using next-generation sequencing. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[42] P. Klenerman,et al. Current knowledge and future perspectives on acute hepatitis C infection. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[43] C. Sabin,et al. P1289 : Understanding and preventing the HCV epidemic among men who have sex with men in the UK: A mathematical modelling analysis , 2015 .
[44] T. Pilot‐Matias,et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. , 2015, JAMA.
[45] K. Reddy,et al. Distinct Features in Natural History and Outcomes of Acute Hepatitis C , 2015, Journal of clinical gastroenterology.
[46] S. Bird,et al. National record linkage study of mortality for a large cohort of opioid users ascertained by drug treatment or criminal justice sources in England, 2005–2009 , 2015, Drug and alcohol dependence.
[47] K. Metzner,et al. Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013 , 2015, Open forum infectious diseases.
[48] M. Leshno,et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm – volume 2 , 2015, Journal of viral hepatitis.
[49] H. Innes,et al. Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? , 2014, Gut.
[50] H. Razavi,et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.
[51] D. De Angelis,et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact , 2014, Journal of viral hepatitis.
[52] Joan Colom I Farran,et al. A policy-maker’s perspective on ‘ECDC and EMCDDA guidance: prevention and control of infectious diseases among people who inject drugs’ , 2014, BMC Infectious Diseases.
[53] J. Lazarus,et al. A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region , 2014, BMC Infectious Diseases.
[54] M. Alavi,et al. Continued low uptake of treatment for hepatitis C virus infection in a large community‐based cohort of inner city residents , 2014, Liver international : official journal of the International Association for the Study of the Liver.
[55] Ross J. Harris,et al. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. , 2014, Journal of hepatology.
[56] R. Geskus,et al. Stabilizing Incidence of Hepatitis C Virus Infection Among Men Who Have Sex With Men in Amsterdam , 2014, Journal of acquired immune deficiency syndromes.
[57] V. Hope,et al. Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey , 2014, Epidemiology and Infection.
[58] S. Hutchinson,et al. Rapid Decline in HCV Incidence among People Who Inject Drugs Associated with National Scale-Up in Coverage of a Combination of Harm Reduction Interventions , 2014, PloS one.
[59] Janet J. Hamilton,et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[60] J. Lazarus,et al. Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention , 2014, PloS one.
[61] D. D. Des Jarlais,et al. Self-reported testing, HIV status and associated risk behaviours among people who inject drugs in Europe: important differences between East and West , 2014, AIDS.
[62] H. Stellbrink,et al. Multiple hepatitis C virus (HCV) reinfections in HIV‐positive men who have sex with men: no influence of HCV genotype switch or interleukin‐28B genotype on spontaneous clearance , 2014, HIV medicine.
[63] H. El‐Serag,et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV , 2014, Hepatology.
[64] Heino Stöver,et al. SMOKE IT! Promoting a change of opiate consumption pattern - from injecting to inhaling , 2014, Harm Reduction Journal.
[65] G. Esmat,et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm , 2014, Journal of viral hepatitis.
[66] M. Buti,et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries , 2014, Journal of viral hepatitis.
[67] G. Dore,et al. Can hepatitis C virus infection be eradicated in people who inject drugs? , 2014, Antiviral research.
[68] H. Wand,et al. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011 , 2014, Journal of viral hepatitis.
[69] S. Oka,et al. Incidence and Risk Factors for Incident Hepatitis C Infection Among Men Who Have Sex With Men With HIV-1 Infection in a Large Urban HIV Clinic in Tokyo , 2014, Journal of acquired immune deficiency syndromes.
[70] M. Thursz,et al. Hepatitis C, A Global Issue: Access to Care and New Therapeutic and Preventive Approaches in Resource-Constrained Areas , 2014, Seminars in Liver Disease.
[71] M. Hellard,et al. Eradication of hepatitis C infection: The importance of targeting people who inject drugs , 2013, Hepatology.
[72] C. Rice,et al. Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource , 2013, Hepatology.
[73] R. Schinazi,et al. Treatment as prevention and cure towards global eradication of hepatitis C virus. , 2013, Trends in microbiology.
[74] P. Bruggmann. Treatment as prevention: The breaking of taboos is required in the fight against hepatitis C among people who inject drugs , 2013, Hepatology.
[75] B. Gazzard,et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM , 2013, AIDS.
[76] J. Rich,et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta‐analysis , 2013, Hepatology.
[77] S. Lenton,et al. The relationship between age and risky injecting behaviours among a sample of Australian people who inject drugs. , 2013, Drug and alcohol dependence.
[78] G. Dore,et al. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[79] G. Dore,et al. Epidemiology and natural history of HCV infection , 2013, Nature Reviews Gastroenterology &Hepatology.
[80] Tara S. Beattie,et al. Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? , 2013, Drug and alcohol dependence.
[81] M. Hellard,et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals , 2013, Hepatology.
[82] M. Hellard,et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[83] P. Vickerman,et al. Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[84] A. de Gottardi,et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[85] R. Detels,et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[86] V. Hope,et al. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association , 2013, Epidemiology and Infection.
[87] W. Miller,et al. Community viral load as a measure for assessment of HIV treatment as prevention. , 2013, The Lancet. Infectious diseases.
[88] M. Salminen,et al. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening , 2013, BMC Infectious Diseases.
[89] D. D. Des Jarlais,et al. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[90] H. Innes,et al. Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. , 2013, The International journal on drug policy.
[91] M. Danta,et al. Sexually transmitted hepatitis C infection: the new epidemic in MSM? , 2012, Current opinion in infectious diseases.
[92] P. Bruggmann. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers , 2012, Journal of viral hepatitis.
[93] C. Lewden,et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. , 2012, Journal of hepatology.
[94] F. Serre,et al. Change in HIV-HCV Risk-Taking Behavior and Seroprevalence Among Opiate Users Seeking Treatment Over an 11-year Period and Harm Reduction Policy , 2012, AIDS and Behavior.
[95] H. Günthard,et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[96] G. Lauer,et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. , 2012, The Lancet. Infectious diseases.
[97] M. Kretzschmar,et al. The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. , 2012, Addiction.
[98] R. Monina Klevens,et al. The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007 , 2012, Annals of Internal Medicine.
[99] P. Vickerman,et al. Cost‐effectiveness of hepatitis C virus antiviral treatment for injection drug user populations , 2012, Hepatology.
[100] H. Hagan. Agent, host, and environment: hepatitis C virus in people who inject drugs. , 2011, The Journal of infectious diseases.
[101] S. Ciesek,et al. Inactivation and survival of hepatitis C virus on inanimate surfaces. , 2011, The Journal of infectious diseases.
[102] Jean-Louis Bara,et al. Hepatitis C transmission in injection drug users: could swabs be the main culprit? , 2011, The Journal of infectious diseases.
[103] M. J. van de Laar,et al. Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[104] J. V. D. van der Meer,et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM , 2011, AIDS.
[105] J. Parry,et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. , 2011, Addiction.
[106] J. Grebely,et al. Management of HCV and HIV infections among people who inject drugs. , 2011, Current opinion in HIV and AIDS.
[107] B. Grady,et al. No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[108] M. Buti,et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference * , 2011, Journal of viral hepatitis.
[109] Louisa Degenhardt,et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.
[110] P. Vickerman,et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. , 2011, Journal of hepatology.
[111] J. Parry,et al. Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots , 2011, Journal of viral hepatitis.
[112] M. Vogel,et al. Trouble with Bleeding: Risk Factors for Acute Hepatitis C among HIV-Positive Gay Men from Germany—A Case-Control Study , 2011, PloS one.
[113] R. Barth,et al. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[114] David L. Thomas,et al. Curing hepatitis C with pills: a step toward global control , 2010, The Lancet.
[115] M. Abdel-hamid,et al. HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt , 2010, Gut.
[116] B. Lindenbach,et al. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. , 2010, The Journal of infectious diseases.
[117] M. Danta,et al. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. , 2010, AIDS.
[118] H. Krarup,et al. Mortality in HIV‐infected injection drug users with active vs cleared hepatitis C virus‐infection: a population‐based cohort study , 2010, Journal of viral hepatitis.
[119] H. Hagan,et al. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. , 2010, The Journal of infectious diseases.
[120] J. Kaldor,et al. Incidence and risk for acute hepatitis C infection during imprisonment in Australia , 2010, European Journal of Epidemiology.
[121] Kelly P Burke,et al. Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence , 2010, Immunologic research.
[122] Judy Gold,et al. Hepatitis C treatment for injection drug users: a review of the available evidence. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[123] I. Stolte,et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic , 2009, AIDS.
[124] E. Oppenheimer,et al. A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region. , 2009, AIDS.
[125] Martin Fisher,et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. , 2009, Gastroenterology.
[126] J. Raffa,et al. Low uptake of treatment for hepatitis C virus infection in a large community‐based study of inner city residents , 2009, Journal of viral hepatitis.
[127] Evan Wood,et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study , 2009, BMJ : British Medical Journal.
[128] U. Siebert,et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality , 2009, BMC public health.
[129] J. Parry,et al. Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics , 2008, Epidemiology and Infection.
[130] J. Parry,et al. Diagnosis of acute hepatitis C virus infection and estimated incidence in low‐ and high‐risk English populations , 2008, Journal of viral hepatitis.
[131] Matthew Hickman,et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review , 2008, The Lancet.
[132] M. Simm,et al. Intranasal transmission of hepatitis C virus: virological and clinical evidence. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[133] A. Branch,et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. , 2008, The Journal of infectious diseases.
[134] N. Hunt,et al. Distributing foil from needle and syringe programmes (NSPs) to promote transitions from heroin injecting to chasing: An evaluation , 2008, Harm reduction journal.
[135] D. Vlahov,et al. Limited Uptake of Hepatitis C Treatment Among Injection Drug Users , 2008, Journal of Community Health.
[136] M. Salminen,et al. European monitoring of notifications of hepatitis C virus infection in the general population and among injecting drug users (IDUs) - the need to improve quality and comparability. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[137] Sanaa M Kamal,et al. Hepatitis C genotype 4: What we know and what we don't yet know , 2008, Hepatology.
[138] D. Hedrich,et al. From margin to mainstream: The evolution of harm reduction responses to problem drug use in Europe , 2008 .
[139] A. Charlett,et al. Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002–2006: is this an outbreak? , 2007, Sexually Transmitted Infections.
[140] J. Kaldor,et al. Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al. , 2007, AIDS.
[141] T. Rhodes,et al. Global estimates of prevalence of HCV infection among injecting drug users. , 2007, The International journal on drug policy.
[142] R. Coutinho,et al. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users , 2007, Addiction.
[143] P. Pradat,et al. Epidemiological characteristics and medical follow-up of 61 patients with acute hepatitis C identified through the hepatitis C surveillance system in France , 2007, Epidemiology and Infection.
[144] J. V. D. van der Meer,et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. , 2007, The Journal of infectious diseases.
[145] J. Kaldor,et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users , 2007, Journal of viral hepatitis.
[146] Anne M Johnson,et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours , 2007, AIDS.
[147] Richard D Moore,et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic , 2006, AIDS.
[148] B. Bell,et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.
[149] M. Prins,et al. Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study , 2006, AIDS.
[150] C. Rouzioux,et al. Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection , 2006, Sexually Transmitted Infections.
[151] J. Desenclos,et al. Les modes de transmission du virus de l’hépatite C : approches méthodologiques , 2006 .
[152] C. Rouzioux,et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy , 2006, AIDS.
[153] J. Kaldor,et al. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies , 2006, Journal of viral hepatitis.
[154] S. Bird,et al. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland , 2005, Hepatology.
[155] Colin W Shepard,et al. Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.
[156] H. Thio,et al. A cluster of acute hepatitis C virus infection among men who have sex with men – results from contact tracing and public health implications , 2005, AIDS.
[157] L. Gambotti,et al. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. , 2005, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[158] R. Garfein,et al. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[159] O. Dalgard. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[160] P. Simmonds,et al. Genetic diversity and evolution of hepatitis C virus--15 years on. , 2004, The Journal of general virology.
[161] Y. Gilleece,et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? , 2004, Sexually Transmitted Infections.
[162] J. Tang,et al. Failure to diagnose recent hepatitis C virus infections in London injecting drug users , 2004, Journal of medical virology.
[163] O. Adeyemi,et al. Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. , 2004, AIDS patient care and STDs.
[164] Y. Hutin,et al. The global burden of disease attributable to contaminated injections given in health care settings , 2004, International journal of STD & AIDS.
[165] H. Hagan,et al. Does bleach disinfection of syringes help prevent hepatitis C virus transmission? , 2003, Epidemiology.
[166] M. Busch,et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. , 2002, The Journal of infectious diseases.
[167] B. Edlin. Prevention and treatment of hepatitis C in injection drug users , 2002, Hepatology.
[168] J. Desenclos,et al. Outbreak of Hepatitis C Virus Infection in a Hemodialysis Unit: Potential Transmission by the Hemodialysis Machine? , 2002, Infection Control & Hospital Epidemiology.
[169] E. Drucker,et al. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. , 2002, The Lancet. Infectious diseases.
[170] M. Memon,et al. Hepatitis C: an epidemiological review , 2002, Journal of viral hepatitis.
[171] P. Lopalco,et al. Risk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: results from the hepatitis surveillance system in Italy. , 2001, Journal of hepatology.
[172] J. Stephenson. Former addicts face barriers to treatment for HCV. , 2001, JAMA.
[173] M. McFarlane,et al. The Internet as a newly emerging risk environment for sexually transmitted diseases. , 2000, JAMA.
[174] B. Edlin,et al. The effect of syringe exchange use on high-risk injection drug users: a cohort study , 2000, AIDS.
[175] L. Hoffer,et al. HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1. , 1999, Journal of acquired immune deficiency syndromes.
[176] P Gaucher,et al. Patient-to-patient transmission of hepatitis C virus during colonoscopy. , 1997, The New England journal of medicine.
[177] D. Desmond,et al. Evaluation of needle and syringe combinations. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[178] J. Patz,et al. Occupational health in surgery: risks extend beyond the operating room. , 1995, The Australian and New Zealand journal of surgery.
[179] E. Buning,et al. PREVENTING AIDS IN DRUG ADDICTS IN AMSTERDAM , 1986, The Lancet.
[180] J. Pawlotsky. Treatment of chronic hepatitis C: current and future. , 2013, Current topics in microbiology and immunology.
[181] D. Rein,et al. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[182] Crime.,et al. WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users.. , 2009 .
[183] J. Kaldor,et al. Hepatitis C Virus Acquisition among Injecting Drug Users: A Cohort Analysis of a National Repeated Cross-sectional Survey of Needle and Syringe Program Attendees in Australia, 1995–2004 , 2008, Journal of Urban Health.
[184] C. B. Hare,et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. , 2006, Journal of acquired immune deficiency syndromes.
[185] J. Duchin,et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. , 2001, American journal of public health.
[186] R. Coutinho,et al. Preventing AIDS in drug addicts in Amsterdam [letter] , 1986 .
[187] S. Ciesek,et al. Transmission of Hepatitis C Virus among People Who Inject Drugs: Viral Stability and Association with Drug Preparation Equipment , 2022 .